The short answer
Ozempic and Wegovy are semaglutide, which engages GLP-1. Mounjaro and Zepbound are tirzepatide, which adds GIP. Retatrutide adds glucagon on top and has no brand name because it is approved nowhere. Reported reductions rise across the three, but come from separate trials, so the comparison is indirect.
Key facts
- Ozempic / Wegovy
- Semaglutide; GLP-1 only; approved
- Mounjaro / Zepbound
- Tirzepatide; GIP + GLP-1; approved
- Retatrutide
- All three receptors; no brand name
- SURMOUNT-5 head-to-head
- Tirz 20.2% vs sema 13.7%
- TRIUMPH-1
- 28.3% at 80 weeks (12 mg)
- Direct comparison
- TRIUMPH-5, completing Nov 2026
Mounjaro, Ozempic, Wegovy: which name is which molecule
Mounjaro and Zepbound are the same molecule (tirzepatide) licensed under two names, the first for type 2 diabetes and the second for weight management. Ozempic and Wegovy are semaglutide, split along the same line. Retatrutide has no brand name at all, because a brand name is something a medicine acquires at approval and retatrutide is approved nowhere; in the literature it is LY3437943. So "retatrutide vs Mounjaro" is retatrutide against tirzepatide, and "retatrutide vs Ozempic" is retatrutide against semaglutide. The comparisons below use the molecule names for that reason.
The one comparison that is direct
SURMOUNT-5 randomised 751 adults to tirzepatide or semaglutide for 72 weeks: 20.2% against 13.7%. Same population, same duration, same trial. That is the strongest form of evidence and it establishes the dual agonist's advantage over the single one.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The comparison that is not
Retatrutide's 28.3% comes from TRIUMPH-1 at 80 weeks; tirzepatide's figures come from SURMOUNT trials at 72. Different populations, different durations, and estimands that may differ. Placing 28.3% next to 20.9% suggests a precision the data does not support. The direction is probably right, the magnitude of the gap is not established.
What will settle it
TRIUMPH-5, registered as NCT06662383, randomises 800 adults to retatrutide or tirzepatide directly, with primary completion in November 2026. Because both are Lilly molecules on modified GIP scaffolds, it isolates the glucagon arm's contribution about as cleanly as a trial can.
The regulatory difference that matters most
Semaglutide and tirzepatide are licensed medicines with marketing authorisations. Retatrutide is investigational and approved nowhere; Lilly has signalled an FDA filing for Q1 2027. Comparing effect sizes across the three obscures the fact that two can be prescribed and one cannot.
Tolerability moves too
More receptors has consistently meant more gastrointestinal burden. TRIUMPH-1 reported 11.3% discontinuation due to adverse events on the 12 mg arm against 4.9% on placebo. SURMOUNT-5 reported the opposite pattern between its two arms (tirzepatide better tolerated than semaglutide on GI discontinuation) so the relationship is not perfectly monotonic.
And none of this concerns research material
Semaglutide and tirzepatide are prescription medicines. Retatrutide is an investigational compound in registered trials. Material supplied for laboratory research is not related to any of them, is not an alternative to any of them, and none of these figures describes it.
Quick reference
| Ozempic / Wegovy | Mounjaro / Zepbound | Retatrutide | |
|---|---|---|---|
| Molecule | Semaglutide | Tirzepatide | LY3437943 |
| Receptors | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + glucagon |
| Molecular weight | 4,114 Da | 4,813 Da | ~4,731 Da |
| Status | Approved | Approved | Investigational |
| Head-to-head | 13.7% (SURMOUNT-5) | 20.2% (SURMOUNT-5) | TRIUMPH-5 pending |
Frequently asked questions
Is retatrutide more effective than tirzepatide?
Its reported figures are higher, but from separate trials with different populations and durations. TRIUMPH-5 tests it directly, completing November 2026.
Which can actually be prescribed?
Semaglutide and tirzepatide hold marketing authorisations. Retatrutide is investigational and approved nowhere.
Does more receptors always mean better tolerated?
No, generally the opposite. Though SURMOUNT-5 found tirzepatide better tolerated than semaglutide on GI discontinuation, so it is not a strict rule.
Is retatrutide better than Mounjaro?
Mounjaro is tirzepatide. Retatrutide's reported 28.3% at 80 weeks is higher than tirzepatide's 20.2% in SURMOUNT-5, but those are different trials with different populations and durations, so the gap is not established. TRIUMPH-5 compares them directly and completes in November 2026.
Is retatrutide the same as Ozempic?
No. Ozempic is semaglutide, a GLP-1 agonist that has been licensed since 2017. Retatrutide is a different molecule engaging three receptors, and it holds no marketing authorisation anywhere.
Is retatrutide better than semaglutide?
Semaglutide is the molecule in Ozempic and Wegovy. Retatrutide's reported reductions are larger, but semaglutide's come from separate trials and semaglutide is licensed while retatrutide is not. No trial has compared the two directly.
Is retatrutide stronger than Mounjaro?
On reported weight reduction the retatrutide figures are higher, but no head-to-head trial has reported. Tolerability moves the other way: TRIUMPH-1 reported 11.3% discontinuation for adverse events on the 12 mg arm.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- RefSURMOUNT-5: Tirzepatide as compared with semaglutide. NEJMnejm.org
- RefTRIUMPH-1 topline results: Eli Lillyinvestor.lilly.com
- TrialClinicalTrials.gov: TRIUMPH-5 (NCT06662383)clinicaltrials.gov
- PubMedCoskun T et al. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- Is Retatrutide FDA Approved? Regulatory Status ExplainedRetatrutide is not FDA approved. It is an investigational peptide in the Phase 3 TRIUMPH programme. Current EMA, MHRA and FDA regulatory status explained.
- Retatrutide Molecular Structure and PropertiesA lipidated 39-mer supplied as a white lyophilised powder. What the structure implies for solubility, handling and analysis.
- What Is a Triple Agonist?One molecule activating three receptors. Why that differs from combination therapy, and what it buys and costs relative to giving three drugs.
- Retatrutide: Spellings, Codes and What Each FindsRetatrutide, LY3437943, reta. Which term finds the science, which finds the market, and the two Lilly codes easily confused with it.
- The History of RetatrutideFrom the 2022 Cell Metabolism discovery paper through Phase 2 in NEJM to the TRIUMPH Phase 3 readouts of 2026 and a signalled FDA filing.